Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics develops rapid, near-patient diagnostic testing for critical care settings through its Symphony™ platform. The company’s lead product candidate, the Symphony™ IL-6 Test, is designed to measure interleukin-6 for sepsis triage, patient monitoring, and risk assessment, with sample-to-result testing described at approximately 20 minutes.
Bluejay news commonly covers SYMON clinical studies, IL-6 biomarker data, conference presentations, manufacturing readiness for Symphony cartridges, antibody production for test components, and regulatory preparation. Company updates also include financing activity, warrant exercises, reverse stock splits, and other capitalization matters. The Symphony System does not yet have U.S. FDA regulatory clearance and requires authorization before it can be marketed as a diagnostic product in the United States.
Summary not available.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its financial results for 2022, highlighting key developments in its Symphony platform, aimed at improving patient outcomes in critical care. The company received positive FDA feedback on expanding its clinical study, pushing the anticipated de novo submission to the first half of 2024. As of December 31, 2022, cash and equivalents decreased to $10.1 million from $19.0 million in 2021. Research and development expenses surged by 262% to $3.0 million, while general and administrative costs increased by 166%. The net loss for the year was $9.3 million, or $0.46 per share, compared to $3.5 million, or $0.41 per share in 2021.
Bluejay Diagnostics (NASDAQ: BJDX) has entered a collaborative agreement with Blood Centers of America (BCA) to address unmet needs in the blood and hospital markets using its Symphony Platform. This partnership allows Bluejay to access BCA's extensive network of over 60 blood centers, potentially enhancing the delivery of critical care solutions. The collaboration aims to support clinical studies and explore Symphony's applications in the blood supply industry. Bluejay's Symphony IL-6 Test, designed for rapid sepsis triage, will play a pivotal role in this initiative, addressing urgent patient care needs.
Bluejay Diagnostics (NASDAQ: BJDX) reported its financial results for the quarter and nine months ending September 30, 2022, highlighting a net loss of $6.9 million, with a net loss per share of $0.34. While revenues saw a slight increase of $250,000 compared to 2021, there were no sales in Q3 2022. R&D expenses rose significantly to $2.8 million as the company expands its clinical program for the Symphony IL-6 test, which has shown promising results in identifying COVID-19 patients at risk for severe illness. Cash reserves stood at $13.3 million, expected to support operations for 12 months.
Bluejay Diagnostics (NASDAQ: BJDX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte Palace Hotel, New York City. CEO Neil Dey and CFO Kenneth Fisher will present on September 13 at 10:30 AM ET. The management team will also engage in one-on-one meetings with investors. Bluejay focuses on rapid, cost-effective diagnostic testing, with its first candidate, an IL-6 Test for sepsis triage, promising results in about 20 minutes. For further details, visit bluejaydx.com.
Bluejay Diagnostics (NASDAQ: BJDX) will host a virtual Key Opinion Leader event on August 25, 2022, focusing on IL-6 Testing in Critical Care settings and its relevance in managing COVID-19 and respiratory failure.
The discussion will feature experts Nathan I. Shapiro, MD, MPH, and Bryan D. Kraft, MD, reflecting on patient care and the Symphony IL-6 test’s potential to enhance clinical decision-making. A live Q&A will follow. The Symphony System aims to provide rapid, near-patient testing, delivering results in approximately 20 minutes.
Bluejay Diagnostics (NASDAQ: BJDX) announced promising results for its Symphony IL-6 Test at AACC 2022, demonstrating a 98% Negative Predictive Value (NPV) for identifying COVID-19 patients at risk for severe illness. The test's clinical sensitivity was found to be 89% and specificity 64%, showing comparable performance to existing FDA EUA-approved tests. Key advantages include faster results (20 minutes), ease of use, and low cost, positioning it as a valuable tool in settings.
Bluejay Diagnostics (NASDAQ: BJDX) reported financial results for Q2 2022, highlighting a net loss of $1.9 million, or $0.10 per share. Cash and cash equivalents fell to $15.3 million from $19.0 million at year-end 2021. The company is advancing its Symphony IL-6 Test, with plans for FDA marketing application submission in Q4 2022. Significant increases in R&D and G&A expenses reflect investment in clinical studies and scalable infrastructure. The Symphony System aims to deliver rapid testing results in 20 minutes, enhancing patient care for life-threatening diseases.
Bluejay Diagnostics (NASDAQ: BJDX) has completed its clinical studies for the Symphony IL-6 Test, a key milestone towards submitting a de Novo Marketing Application to the FDA by year-end. The studies included a reference range study and validation studies, the results of which will be revealed at the AACC Annual Scientific Meeting from July 26-28, 2022. The Symphony System aims to provide rapid, near-patient testing with results in approximately 20 minutes, enhancing decision-making in critical care settings.
Bluejay Diagnostics (NASDAQ: BJDX) announced that the FDA has agreed to consider its De Novo submission plan for the Symphony IL-6 Test. This follows feedback on a January 2022 pre-submission package indicating potential for the test's regulatory pathway. CEO Neil Dey expressed optimism about advancing the Symphony IL-6 Test towards FDA marketing application, expected by year-end 2022. The Symphony System aims to provide rapid, efficient patient testing with results in approximately 20 minutes, targeting improved disease management.